RxDoctor Payments Data

Calvin McAllister, MD

Radiation Oncology · Idaho Falls, IDNPI 1952404097

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,157, more than ten times the $212 reported in 2019. Among radiation oncology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,140in general payments, 2019–2025

Across 288 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$836
  • Bayer$410
  • Novartis$312
  • Johnson & Johnson$296
  • Merck$282
  • AbbVie$262
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$6,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca37$836
Bayer31$410
Novartis16$312
Johnson & Johnson(2 entities)15$296
Merck13$282
AbbVie12$262
Boston Scientific4$193
Daiichi Sankyo Inc.9$185
Regeneron Healthcare Solutions, Inc.3$171
Tersera Therapeutics LLC8$165
Lilly USA, LLC9$164
Pfizer9$162
Exelixis Inc.2$157
Isoray, Inc5$156
Amgen9$140
E.r. Squibb & Sons, L.L.C.1$125
Takeda Pharmaceuticals U.S.A., Inc.5$103
Dendreon Pharmaceuticals LLC5$91
Beone Medicines USA, Inc.3$90
Stemline Therapeutics Inc.4$82
Sobi, Inc4$81
Jazz Pharmaceuticals Inc.3$81
Incyte Corporation4$76
Genentech USA, Inc.3$75
Pharmacyclics LLC, An Abbvie Company4$72
Blueprint Medicines Corporation3$66
Astellas Pharma US Inc4$64
Siemens Medical Solutions USA, Inc.3$62
Seagen Inc.4$62
Spectrum Pharmaceuticals Inc.3$59
Iovance Biotherapeutics, Inc.2$56
Puma Biotechnology, Inc.2$55
Boehringer Ingelheim2$51
Pharmacosmos Therapeutics Inc.3$48
Sanofi3$44
Novocure Inc.2$42
Sumitomo Pharma America, Inc.2$41
Deciphera Pharmaceuticals Inc.2$38
Foundation Medicine, Inc.1$38
GSK2$36
Beigene USA, Inc.1$35
Servier Pharmaceuticals LLC2$34
Legend Biotech USA Inc.1$33
Adaptive Biotechnologies Corporation1$33
G1 Therapeutics, Inc.2$30
Fresenius Kabi USA, LLC2$30
Blue Earth Diagnostics1$27
Geron Corporation1$25
Medtronic1$24
Eisai Inc.1$23
CTI Biopharma Corp.1$23
Syndax Pharmaceuticals, Inc.1$22
Palette Life Sciences, Inc.1$21
EUSA Pharma (US) LLC1$21
Acrotech Biopharma Inc.1$20
Genmab U.S., Inc.1$20
ADC Therapeutics America, Inc.1$20
Karyopharm Therapeutics Inc.1$20
Myriad Genetic Laboratories, Inc.1$17
Springworks Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,140 in reported general payments places this provider in the 95th percentile of 22 radiation oncology providers in Idaho.

See all radiation oncology providers in Idaho

Medicare billing

Part B allowed, 2024
$350,666
Medicare patients
258
Services billed
3,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl120$996
Ondansetron Hcl13$884
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$242

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →